BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSX - US1011371077 - Common Stock
76.8 EUR
-0.6 (-0.78%)
BSX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 67 industry peers in the Health Care Equipment & Supplies industry. BSX scores excellent on profitability, but there are some minor concerns on its financial health. BSX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make BSX suitable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year BSX was profitable.
- BSX had a positive operating cash flow in the past year.
- Of the past 5 years BSX 4 years were profitable.
- Each year in the past 5 years BSX had a positive operating cash flow.
1.2 Ratios
- With a decent Return On Assets value of 6.54%, BSX is doing good in the industry, outperforming 73.13% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 11.93%, BSX is in the better half of the industry, outperforming 71.64% of the companies in the same industry.
- BSX has a Return On Invested Capital of 8.09%. This is in the better half of the industry: BSX outperforms 68.66% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 9.84%.
- The last Return On Invested Capital (8.09%) for BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
- BSX has a better Profit Margin (14.42%) than 83.58% of its industry peers.
- BSX's Profit Margin has declined in the last couple of years.
- BSX has a Operating Margin of 19.40%. This is amongst the best in the industry. BSX outperforms 83.58% of its industry peers.
- In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
- BSX's Gross Margin of 68.57% is fine compared to the rest of the industry. BSX outperforms 77.61% of its industry peers.
- In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
- BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, BSX has more shares outstanding
- Compared to 5 years ago, BSX has more shares outstanding
- Compared to 1 year ago, BSX has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 5.09 indicates that BSX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of BSX (5.09) is better than 85.07% of its industry peers.
- BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 3.03, BSX is doing good in the industry, outperforming 73.13% of the companies in the same industry.
- BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of BSX (0.48) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.09 |
ROIC/WACC0.83
WACC9.72%
2.3 Liquidity
- A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
- BSX has a Current ratio of 1.51. This is comparable to the rest of the industry: BSX outperforms 46.27% of its industry peers.
- A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
- The Quick ratio of BSX (0.96) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
- BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
- The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
- BSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.62%.
- The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
- Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.06% on average per year.
- BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.60% yearly.
EPS Next Y22.13%
EPS Next 2Y18.12%
EPS Next 3Y16.5%
EPS Next 5Y15.06%
Revenue Next Year20.91%
Revenue Next 2Y16.08%
Revenue Next 3Y14.2%
Revenue Next 5Y12.6%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 30.24, BSX can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of BSX is on the same level as its industry peers.
- BSX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.38.
- The Price/Forward Earnings ratio is 25.51, which means the current valuation is very expensive for BSX.
- BSX's Price/Forward Earnings is on the same level as the industry average.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. BSX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.24 | ||
| Fwd PE | 25.51 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BSX is valued a bit more expensive than 62.69% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 61.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.64 | ||
| EV/EBITDA | 27.96 |
4.3 Compensation for Growth
- BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- BSX has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.50% in the coming years.
PEG (NY)1.37
PEG (5Y)3.16
EPS Next 2Y18.12%
EPS Next 3Y16.5%
5. Dividend
5.1 Amount
- No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:BSX (1/16/2026, 7:00:00 PM)
76.8
-0.6 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap113.85B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts85.5
Price Target108.94 (41.85%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-1.18%
PT rev (3m)0.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.29%
EPS NY rev (1m)0.01%
EPS NY rev (3m)1.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.24 | ||
| Fwd PE | 25.51 | ||
| P/S | 6.84 | ||
| P/FCF | 34.64 | ||
| P/OCF | 28.63 | ||
| P/B | 5.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.96 |
EPS(TTM)2.54
EY3.31%
EPS(NY)3.01
Fwd EY3.92%
FCF(TTM)2.22
FCFY2.89%
OCF(TTM)2.68
OCFY3.49%
SpS11.22
BVpS13.57
TBVpS-1.15
PEG (NY)1.37
PEG (5Y)3.16
Graham Number27.85
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.09 |
F-Score6
WACC9.72%
ROIC/WACC0.83
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.13%
EPS Next 2Y18.12%
EPS Next 3Y16.5%
EPS Next 5Y15.06%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.91%
Revenue Next 2Y16.08%
Revenue Next 3Y14.2%
Revenue Next 5Y12.6%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.61%
EBIT Next 3Y20.84%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 4 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 30.24 and the Price/Book (PB) ratio is 5.66.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 22.13% in the next year.